您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Oxaliplatin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Oxaliplatin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Oxaliplatin图片
CAS NO:61825-94-3
包装与价格:
包装价格(元)
5mg电议
50mg电议
100mg电议
200mg电议
500mg电议
1 g电议
5 g电议

产品名称
奥沙利铂
产品介绍
Oxaliplatin 是一种DNA 合成抑制剂。Oxaliplatin 会导致 DNA 交联损伤,阻止 DNA 复制和转录并导致细胞死亡。Oxaliplatin 以时间依赖方式抑制人黑色素瘤细胞系 C32 和 G361,IC50值分别为 0.98 μM 和 0.14 μM。Oxaliplatin 可以诱导细胞自噬 (autophagy)。
生物活性

Oxaliplatin is aDNA synthesisinhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and inducesapoptosis. Oxaliplatin can be used forcancerresearch[1][2][3].

IC50& Target

IC50: DNA synthesis[1]

体外研究
(In Vitro)

Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1].
Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2].
Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3].

Cell Viability Assay[1]

Cell Line:HCC, HCCLM3 and Hep3B cells
Concentration:24, 48 and 72 hours
Incubation Time:2, 4, 8, 16, 32, 64 and 128 μM
Result:Decreased cell viability in a dose- and time-dependent manner.

Cell Cycle Analysis[1]

Cell Line:HCCLM3 and Hep3B cells
Concentration:10 μM
Incubation Time:24 hours
Result:Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).

Cell Cycle Analysis[1]

Cell Line:HCCLM3 cells
Concentration:10 μM
Incubation Time:48 hours
Result:Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.
体内研究
(In Vivo)

Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth[1].

Animal Model:Nude mice[1]
Dosage:5 and 10 mg/kg
Administration:Intraperitoneal injection; for 32 days
Result:Reduced tumor volume in HCCLM3 tumor xenografts.
Clinical Trial
分子量

397.29

性状

Solid

Formula

C8H14N2O4Pt

CAS 号

61825-94-3

中文名称

奥沙利铂

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

H2O : 2.17 mg/mL(5.46 mM;ultrasonic and warming and heat to 60℃;DMSO can inactivate Oxaliplatin's activity)

DMF : 1.67 mg/mL(4.20 mM;Need ultrasonic;DMSO can inactivate Oxaliplatin's activity)

Ethanol :< 1 mg/mL(insoluble;DMSO can inactivate Oxaliplatin's activity)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.5171 mL12.5853 mL25.1705 mL
5 mM0.5034 mL2.5171 mL5.0341 mL
10 mM---------
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 5% w/v Glucose Solution

    Solubility: 3.33 mg/mL (8.38 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: PBS

    Solubility: 1.92 mg/mL (4.83 mM); Clear solution; Need ultrasonic and warming and heat to 60℃

*以上所有助溶剂都可在本网站选购。